BR0206595A - Composto, composição farmacêutica, e uso de um composto - Google Patents
Composto, composição farmacêutica, e uso de um compostoInfo
- Publication number
- BR0206595A BR0206595A BR0206595-9A BR0206595A BR0206595A BR 0206595 A BR0206595 A BR 0206595A BR 0206595 A BR0206595 A BR 0206595A BR 0206595 A BR0206595 A BR 0206595A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutical composition
- antagonists
- receptor
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
"COMPOSTO, COMPOSIçãO FARMACêUTICA, E, USO DE UM COMPOSTO". A presente invenção refere-se aos compostos de fórmula I: que são antagonistas de receptor 5-HT6.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26499601P | 2001-01-30 | 2001-01-30 | |
PCT/US2002/000502 WO2002060871A2 (en) | 2001-01-30 | 2002-01-17 | Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-ht6 receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0206595A true BR0206595A (pt) | 2004-07-13 |
Family
ID=23008516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0206595-9A BR0206595A (pt) | 2001-01-30 | 2002-01-17 | Composto, composição farmacêutica, e uso de um composto |
Country Status (12)
Country | Link |
---|---|
US (2) | US7230011B2 (pt) |
EP (1) | EP1377580B1 (pt) |
JP (1) | JP2004526699A (pt) |
CN (1) | CN1275967C (pt) |
AT (1) | ATE340795T1 (pt) |
AU (1) | AU2002236730B2 (pt) |
BR (1) | BR0206595A (pt) |
CA (1) | CA2433351A1 (pt) |
DE (1) | DE60214990T2 (pt) |
ES (1) | ES2272667T3 (pt) |
MX (1) | MXPA03006605A (pt) |
WO (1) | WO2002060871A2 (pt) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2222827B1 (es) * | 2003-07-30 | 2006-03-01 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 5-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos. |
ES2222829B1 (es) * | 2003-07-30 | 2006-03-01 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 4-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos. |
ES2222828B1 (es) * | 2003-07-30 | 2006-04-16 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos. |
ES2222832B1 (es) * | 2003-07-30 | 2006-02-16 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos. |
ES2222830B1 (es) * | 2003-07-30 | 2006-02-16 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 7-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos. |
NZ548743A (en) * | 2004-01-02 | 2009-07-31 | Suven Life Sciences Ltd | Novel indeno[2,1A]indenes and isoindol[2,1-A]indoles |
WO2007004959A1 (en) * | 2005-07-05 | 2007-01-11 | Astrazeneca Ab | New compounds, process for their preparation, intermediates, pharmaceutical compositions and their use in the treatment of 5-ht6 mediated disorders such as alzheimer's disease, cognitive disorders, cognitive impairment associated with schizophrenia, obesity and parkinson's disease |
US20080015214A1 (en) * | 2005-10-24 | 2008-01-17 | Bignan Gilles C | 3-piperidin-4-yl-indole orl-1 receptor modulators |
JP2010519171A (ja) | 2006-02-17 | 2010-06-03 | メモリー・ファーマシューティカルズ・コーポレイション | 5−ht6受容体親和性を有する化合物 |
AR061637A1 (es) * | 2006-06-26 | 2008-09-10 | Epix Delaware Inc | Composiciones y metodos de tratamiento de trastornos del snc |
CA2667547C (en) * | 2006-10-27 | 2014-07-29 | Boehringer Ingelheim International Gmbh | Piperidyl-propane-thiol ccr3 modulators |
US8148403B2 (en) * | 2006-10-27 | 2012-04-03 | Boehringer Ingelheim International Gmbh | Substituted piperidyl-propane-thiols |
CA2670717C (en) | 2007-01-08 | 2012-01-10 | Suven Life Sciences Limited | 5-(heterocyclyl)alkyl-n-(arylsulfonyl)indole compounds and their use as 5-ht6 ligands |
DK2155674T3 (da) | 2007-05-03 | 2011-09-26 | Suven Life Sciences Ltd | Aminoalkoxy-aryl-sulfonamidforbindelser og anvendelse heraf som 5-HT6-ligander |
BRPI0816571A2 (pt) | 2007-10-26 | 2015-12-22 | Suven Life Sciences Ltd | "composto, processo para preparação do composto, composição farmacêutica, agente e método para o tratamento de uma doença ou uma desordem do sistema nervoso central relacionada à ou afetada pelo recptor 5-ht6" |
KR101308819B1 (ko) | 2008-09-17 | 2013-09-13 | 수벤 라이프 사이언시스 리미티드 | 아릴 술폰아미드 아민 화합물 및 5-ht6 리간드로서의 용도 |
US8318725B2 (en) | 2008-09-17 | 2012-11-27 | Suven Life Sciences Limited | Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands |
US8563567B2 (en) | 2009-12-30 | 2013-10-22 | Arqule, Inc. | Substituted heterocyclic compounds |
SG181992A1 (en) | 2010-01-05 | 2012-08-30 | Suven Life Sciences Ltd | Sulfone compounds as 5-ht6 receptor ligands |
KR101250606B1 (ko) * | 2011-01-24 | 2013-04-03 | 이화여자대학교 산학협력단 | 5-ht6 수용체 억제 작용을 갖는 신규한 벤조티아졸 및 벤즈이소티아졸유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물 |
EP3718547A1 (en) * | 2011-10-03 | 2020-10-07 | The University of Utah Research Foundation | Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome |
EP3082802B1 (en) | 2013-12-03 | 2020-02-26 | Iomet Pharma Ltd. | Tryptophan-2,3-dioxygenase (tdo) and/or indolamine-2,3-dioxygenase (ido) inhibitors and their use |
JP6515175B2 (ja) | 2014-07-08 | 2019-05-15 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. | 芳香族ヘテロ環誘導体及びその医薬的適用 |
CA2975157C (en) * | 2015-01-30 | 2019-09-17 | Pfizer Inc. | Sulfonamide-substituted indole modulators of rorc2 and methods of use thereof |
EP3331530A4 (en) * | 2015-08-03 | 2018-12-19 | Raze Therapeutics Inc. | Mthfd2 inhibitors and uses thereof |
CN115521307B (zh) * | 2022-09-30 | 2023-09-22 | 甘肃皓天医药科技有限责任公司 | 一种5-卤代-7-氮杂吲哚的制备方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2126399C1 (ru) * | 1991-11-25 | 1999-02-20 | Пфайзер Инк. | Производные индола, замещенные индолы и способ ингибирования 5ht1 рецептора серотонина |
US5521196A (en) | 1994-10-05 | 1996-05-28 | Eli Lilly And Company | 5-HT1F agonists for the treatment of migraine |
US5521197A (en) | 1994-12-01 | 1996-05-28 | Eli Lilly And Company | 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists |
DE4444864A1 (de) * | 1994-12-16 | 1996-06-20 | Bayer Ag | Verwendung von 5-Acyl-1,4-dihydropyridinen |
CA2215322A1 (en) | 1995-03-20 | 1996-09-26 | Stephen Warren Kaldor | 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)-and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists |
WO1997013512A1 (en) | 1995-10-10 | 1997-04-17 | Eli Lilly And Company | N-[2-substituted-3-(2-aminoethyl)-1h-indol-5-yl]-amides: new 5-ht1f agonists |
WO1998015545A1 (en) | 1996-10-08 | 1998-04-16 | Eli Lilly And Company | New serotonin 5-ht1f agonists |
US6133287A (en) | 1998-03-24 | 2000-10-17 | Allelix Biopharmaceuticals Inc. | Piperidine-indole compounds having 5-HT6 affinity |
ATE375990T1 (de) | 1999-04-21 | 2007-11-15 | Nps Allelix Corp | Piperidin-indol derivate mit 5-ht6 affinität |
JP2003506348A (ja) | 1999-07-28 | 2003-02-18 | 麒麟麦酒株式会社 | Ccr−3受容体のインヒビターとしての尿素誘導体 |
-
2002
- 2002-01-17 DE DE60214990T patent/DE60214990T2/de not_active Expired - Fee Related
- 2002-01-17 ES ES02703087T patent/ES2272667T3/es not_active Expired - Lifetime
- 2002-01-17 US US10/466,969 patent/US7230011B2/en not_active Expired - Fee Related
- 2002-01-17 JP JP2002561022A patent/JP2004526699A/ja active Pending
- 2002-01-17 AT AT02703087T patent/ATE340795T1/de not_active IP Right Cessation
- 2002-01-17 CN CNB028043480A patent/CN1275967C/zh not_active Expired - Fee Related
- 2002-01-17 AU AU2002236730A patent/AU2002236730B2/en not_active Ceased
- 2002-01-17 CA CA002433351A patent/CA2433351A1/en not_active Abandoned
- 2002-01-17 WO PCT/US2002/000502 patent/WO2002060871A2/en active IP Right Grant
- 2002-01-17 EP EP02703087A patent/EP1377580B1/en not_active Expired - Lifetime
- 2002-01-17 BR BR0206595-9A patent/BR0206595A/pt not_active IP Right Cessation
- 2002-01-17 MX MXPA03006605A patent/MXPA03006605A/es active IP Right Grant
-
2007
- 2007-01-18 US US11/624,389 patent/US20070135484A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2433351A1 (en) | 2002-08-08 |
CN1489591A (zh) | 2004-04-14 |
AU2002236730B2 (en) | 2006-06-15 |
US20040102481A1 (en) | 2004-05-27 |
WO2002060871A3 (en) | 2003-09-12 |
DE60214990D1 (de) | 2006-11-09 |
WO2002060871A2 (en) | 2002-08-08 |
ES2272667T3 (es) | 2007-05-01 |
WO2002060871A8 (en) | 2003-12-18 |
CN1275967C (zh) | 2006-09-20 |
MXPA03006605A (es) | 2003-09-22 |
EP1377580A2 (en) | 2004-01-07 |
DE60214990T2 (de) | 2007-04-05 |
US20070135484A1 (en) | 2007-06-14 |
ATE340795T1 (de) | 2006-10-15 |
US7230011B2 (en) | 2007-06-12 |
EP1377580B1 (en) | 2006-09-27 |
JP2004526699A (ja) | 2004-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0206595A (pt) | Composto, composição farmacêutica, e uso de um composto | |
NO20034289D0 (no) | N-(2-aryletylbenzylaminer som antagonister av 5-HT6- reseptoren | |
NO20041504L (no) | Lactamderivater som antagonister for humane 11CBY reseptorer. | |
DK1337518T3 (da) | Piperazinylpyrazinforbindelser som antagonister for serotonin-5-HT2-receptoren | |
CY1108573T1 (el) | Ανταγωνιστες νρυυ5 | |
SE0101675D0 (sv) | Novel composition | |
BRPI0417717A (pt) | composto, composição farmacêutica, e, uso de um composto | |
BRPI0715579A2 (pt) | "composto, composição farmacêutica e uso de um composto" | |
SE0302760D0 (sv) | New compounds | |
MXPA03004549A (es) | Derivados de 3-arilindola y su uso como agonistas del receptor cb2. | |
PL369887A1 (en) | Pharmaceutical nanoparticulate composition of a tachykinin receptor antagonist | |
BR0015963A (pt) | Compostos de uréia antagonistas receptor muscarìnico, composições farmacêuticas compreendendo tais compostos e método de preparação destes compostos | |
NO20060195L (no) | Kinolylamidderivater som CCR-5-antagonister | |
BRPI0414539A (pt) | composto, composição farmacêutica, e, uso de um composto | |
CY1109998T1 (el) | Ενδυναμωτες υποδοχεων γλουταμινικου | |
EA200300829A1 (ru) | Производные 1-арил- или 1-алкилсульфонилбензазола в качестве лигандов 5-гидрокситриптамина-6 | |
YU80902A (sh) | Novi indolin-2-on derivati, njihovo dobijanje i farmaceuski oblici koji ih sadrže | |
ES2243579T3 (es) | Derivados de pirazolopirideno. | |
UY27852A1 (es) | Difenilazatidinonas cationicamente sustituidas, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso. | |
WO2005060959A8 (en) | Pyrazole derivatives and use thereof as orexin receptor antagonists | |
TR200002896T2 (tr) | Kalsilitik Bileşimler | |
SE9901077D0 (sv) | Novel use | |
BR0212353A (pt) | Composto, composição farmacêutica, e, uso de um composto | |
SE9801494D0 (sv) | Novel use | |
NO20014855L (no) | N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A E 9A ANUIDADE(S). |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2103 DE 26/04/2011. |